IC7 Stock Chart & Stats
€145.00
-€1.00(-0.68%)
At close: 4:00 PM EDT
€145.00
-€1.00(-0.68%)
Day’s Range― - ―
52-Week Range€93.00 - €160.00
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€3.89B
Enterprise Value€4.66K
Total Cash (Recent Filing)€298.30M
Total Debt (Recent Filing)€1.27B
Price to Earnings (P/E)152.6
Beta0.50
Next Earnings
Nov 09, 2026EPS Estimate
1.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding25,007,038
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-47.74
Price to Book (P/B)1.66
Price to Sales (P/S)1.58
P/FCF Ratio38.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€166.11Price Target Upside14.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)7.09
Revenue Forecast (FY)€1.89B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueICU Medical’s core business sells single-use infusion and vascular consumables that are routinely replaced per patient. That creates repeat purchasing, customer stickiness and predictable recurring revenue streams, supporting durable cash flow and resilience across care settings.
Improving Cash GenerationFree cash flow has rebounded materially and was a $62M quarterly print, with FCF surge versus the prior period. Strong cash conversion strengthens liquidity, funds debt paydowns, funds integration costs and supports investment, making operations more self-sustaining over the medium term.
Leverage Reduction / Balance-sheet ProgressManagement has paid down debt, improving debt-to-equity and lowering net leverage to ~2.3x with a clear ~2x target. Reduced leverage enhances financial flexibility, lowers interest burden risk, and increases capacity to invest in strategic programs or withstand macro stress over 2–6 months.
Bears Say
Thin, Volatile ProfitabilityWhile recent results show a rebound, ICU Medical’s margins and returns remain modest and historically volatile, including multi-year losses. Low net margin and weak ROE limit resilience to shocks and mean earnings durability and cash generation could slip if headwinds re-emerge.
Tariffs And Currency HeadwindsMaterial and recurring tariff costs plus persistent adverse FX have meaningfully dragged results. These are structural geographic and policy exposures that reduce margins and create earnings volatility, making long-term margin sustainability more uncertain absent pricing or cost offsets.
JV Deconsolidation & Product Timing RiskThe mid‑2025 IV Solutions JV deconsolidation compresses reported growth and obscures comparability; the JV is expected near-breakeven. Coupled with timing uncertainty around Medfusion 5000 resubmission and OEM revenue wind-down, this creates structural visibility and contribution risks to near-term revenue and profits.
ICU Medical News
IC7 FAQ
What was Icu Medical’s price range in the past 12 months?
Icu Medical lowest stock price was €93.00 and its highest was €160.00 in the past 12 months.
What is Icu Medical’s market cap?
Icu Medical’s market cap is €3.89B.
When is Icu Medical’s upcoming earnings report date?
Icu Medical’s upcoming earnings report date is Nov 09, 2026 which is in 86 days.
How were Icu Medical’s earnings last quarter?
Icu Medical released its earnings results on Aug 06, 2026. The company reported €2.051 earnings per share for the quarter, beating the consensus estimate of €1.656 by €0.395.
Is Icu Medical overvalued?
According to Wall Street analysts Icu Medical’s price is currently Undervalued.
Does Icu Medical pay dividends?
Icu Medical does not currently pay dividends.
What is Icu Medical’s EPS estimate?
Icu Medical’s EPS estimate is 1.85.
How many shares outstanding does Icu Medical have?
Icu Medical has 25,007,038 shares outstanding.
What happened to Icu Medical’s price movement after its last earnings report?
Icu Medical reported an EPS of €2.051 in its last earnings report, beating expectations of €1.656. Following the earnings report the stock price went up 10.49%.
Which hedge fund is a major shareholder of Icu Medical?
Currently, no hedge funds are holding shares in DE:IC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ICU Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€166.11 (14.56% Upside)
€166.11 (14.56% Upside)
Blogger Sentiment
Bullish
DE:IC7 Sentiment 67%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth €3.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Icu Medical
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
IC7 Company Deck
IC7 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a positive operational and financial trajectory: record revenues in key businesses, margin expansion, raised full-year guidance, and strong free cash flow enabled a $50M debt paydown and progress toward a ~2x leverage target. Headwinds remain — notably tariffs, currency impacts, restructuring charges, and a weakened Vital Care reported performance due to JV deconsolidation — and there is some timing uncertainty around regulatory resubmissions and project phasing. On balance, the company emphasized momentum and achievable margin/cash goals despite macro and one-time pressures.View all DE:IC7 earnings summariesIC7 Stock 12 Month Forecast
Average Price Target
€166.11
▲(14.56% Upside)